Podcasts about compounds

Urolithin-A and Spermidine: Compounds That Aid in Cellular Health AND Anti-Aging! Mother Nature and Father Time are undefeated! That doesn't mean we have to go quietly into that good night! Nope - we can live intentionally! Supplements - Vitamins - Mindsets - Bio Hacks - Science - Food - Exercise - Sleep - Habits - Relationships - all wrapped up in data, stories, and conversations! Join Clint Powell and his co-hosts to talk about aging from 18 to 80! (we are not diagnosing or suggesting treatments - this is for entertainment purposes - please consult your doctor or medical professionals before starting/stopping any medications and/or taking any supplements!) POWERED BY THE VASCULAR INSTITUTE OF CHATTANOOGA: https://vascularinstituteofchattanooga.com/ Sponsored by: Alchemy MedSpa: https://alchemymedspachatt.com/ Optimize U Chattanooga: https://optimizeucenters.com/locations/chattanooga-tennessee/ ALL THINGS JEFF STYLES: www.thejeffstyles.com PART OF THE NOOGA PODCAST NETWORK: www.noogapodcasts.com Please consider leaving us a review on Apple and giving us a share to your friends! This podcast is powered by ZenCast.fm

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u

Chemical compounds with H2O create bacteria.

Karl Matthews, Ph.D., Professor of Microbial Food Safety at Rutgers University, discusses ways to eliminate pathogens like Salmonella, E. coli O157:H7 and Listeria from fresh fruits and vegetables. He highlights the importance of preventative measures from farm to table, including the use of water antimicrobials, like chlorine, and photosensitizers, like curcumin. Watch this episode: https://youtu.be/6Wkef9RyUVE Ashley's Biggest Takeaways We consume billions of microorganisms in the food that we eat each day. Fresh fruits and vegetables that are not thermally processed are likely to carry a higher microbial load than cooked foods. Many of those microbes are not concerning to human health. However, when pathogens of human health concern are present, the food can become unsafe to eat. Scientists use many methods from pre-harvest through post-harvest to keep food free of human pathogens. Water antimicrobials, such as chlorine, and photodynamic inactivation using photosensitizers, such as curcumin, are 2 preventative measures that Matthews and colleagues are investigating. Curcumin is a natural chemical compound found in the turmeric plant. It is responsible for giving tumeric its yellow color. Curcumin is also a photosensitizer, meaning that it can absorb light energy and transfer it to another molecule to initiate chemical reactions that produce cytotoxic singlet oxygen. Featured Quotes When I look at [what makes fruits and vegetables safe to eat] as far as from a microbiological perspective, it's are they free of pathogens of human health concern? And so, we might think about organisms, such as Salmonella or the Shiga toxin producing E coli or Listeria. There are a number of processes and initiatives that are put into place, from the pre-harvest through post-harvest levels to try to ensure that the product is not contaminated with microorganisms of human health concern. Each day, we're consuming literally billions of microorganisms in the foods that we eat, and particularly the raw fruits and vegetables that we're eating that are not being thermally processed in any fashion by which you might reduce the microbial load. Oftentimes we think about the bacteria that might well be there. But we do know that there's viruses that could be present. There's certain type of protozoa that might be present. Many of us know of norovirus and the concerns associated with that particular pathogen. So, there's a multitude of microorganisms that might well be associated with fresh fruits and vegetables, but there's really a very limited number or types that are actually of concern from a human health standpoint. In my program, we're working on E. coli O157:H7, in particular. It's a certain serotype of E. coli, a diarrheagenic E. coli, what's also known as a Shiga toxin-producing E. coli. We work with Salmonella, and we work with Listeria monocytogenes, but there's other microorganisms, such as Campylobacter, Yersinia, Staphylococcus aureus. All of those types of pathogens can also be associated with foods—and different types of foods, at that—and be of concern to the general public—the consumer. If we look at a lot of the processing of foods that are taking place, not only here in the United States, but globally, many times, what will happen is they're utilizing some type of a water antimicrobial, and I stress that because, oftentimes, these antimicrobials are added to the water to control the microbial load in the water. So, ultimately, you're not basically putting on water and putting on a whole load of microorganisms along with it. And also, you can prevent cross contamination through that. Here in the U.S. and elsewhere, we'll often put additional chlorine into the water. So, let's say we're increasing the chlorine concentration to 20 parts per million, or 50 parts per million, or maybe in poultry processing, they're utilizing peracetic acid. These are 2 common antimicrobials that are being used. What we wanted to do is find out could we utilize some other types of methods that might well control microorganisms on the commodity itself? And that's where we started looking at photodynamic inactivation and coupling that with the use of a photosensitizer. And in this particular case, the photosensitizer we were using was curcumin. The reason for working with curcumin is that it's naturally used in foods as a food dye. It's also used as a flavoring agent, and so forth. So, it's there, and it's being used—not just in the U.S., but [also] globally. And we thought we would try to see if we utilize this compound, could we have an additive effect to it? If you apply certain wavelengths of light, you can inactivate microorganisms, but if you apply that wavelength to something like a photosensitizer type molecule (curcumin), you could generate singlet oxygen molecules. And those singlet oxygen molecules would act like little explosions on the cell membrane and basically blow it apart and, therefore, inactivate the organism. We looked at the ability of this to inactivate Listeria monocytogenes, Salmonella, as well as E. coli O157:H7, so these Shiga toxin-producing E. coli, and what we did indeed find is that it was very effective. We looked at it in comparison to peracetic acid use in the poultry industry, and we found it to be equivalent, at least to treatments that we were utilizing on poultry skin, with inactivation of the microorganisms, such as Listeria, on the poultry skin. So, it is really exciting. Links for This Episode ​​​​​​Preventing Foodborne Outbreaks Starts in the Field. Influences of photosensitizer curcumin on microbial survival and physicochemical properties of chicken during storage.

Maple-derived compounds, especially epicatechin gallate (ECG), stop cavity-causing bacteria from attaching to your teeth and forming plaque Unlike chemical mouthwashes, maple polyphenols are safe to swallow, making them a better option for children and adults Green and black tea also contain ECG, giving you an easy daily source of natural cavity protection Reducing sugary and acidic drinks cuts off the main fuel that bacteria use to erode enamel and cause decay Homemade eggshell toothpaste and oil pulling with coconut oil provide simple, natural ways to strengthen teeth and reduce harmful bacteria

Welcome back to Podgap, the podcast that helps you explore the beauty and rhythm of the Persian language.In this episode, Hanieh and Mohsen take you on a journey into one of the most playful and musical parts of the Persian language: echo compounds—those catchy word pairs like rizé-mizé or āt o āshqāl that add rhythm, humor, and charm to everyday conversations.You'll learn what makes these expressions special, how native speakers use them in real life, and how you can sprinkle them into your own Persian to sound more natural and fluent.With plenty of fun examples, a guessing game, and a short challenge for you to try, this episode is all about enjoying the music of words in Persian.So grab your headphones, get ready to learn, and let's dive in!If Podgap makes your Persian learning journey easier and more enjoyable, share it with your friends — it truly means the world to us!We'd also love to hear from you: drop us a message anytime at podgapp@gmail.com

Episode 266. How To Trust Your Body - Everything CompoundsThis week on Confidence From Within Podcast, and explore the idea that all our effort compounds, so even if results feel slow, we can still find a way to trust our bodies and trust the process.Here's what you'll learn in this episode: How I define success, differently than popular beliefsWhy impatience is often the reason most diets failThe difference between 2 types of patience and why this matters Given life is uncertain, how can we raise our chances of success What to do when life is busy and it is harder to move forward and make progressMy strategy to trust my body (and life) more and more each day Resources Mentioned In This Episode: Get my 14-Cravings Release Challenge™ that I described in this episode = get it hereCurious about how your DNA can help you get to your wellness goals, without all the trial-and-error? Start hereIf you missed our 5-year celebration episode (EP. 264 Five Years in the Making: Lessons You Can't Google), listen to it here If you enjoyed today's episode, please:Post a screenshot & key takeaway on your Instagram story and tag us @naturally.joyous so we can repost you Leave us a 5-star review on Apple Podcasts, HERE is howSubscribe to the Confidence From Within Podcast, we release new episodes every Friday! Hosted on Acast. See acast.com/privacy for more information.

In this latest installment of Noid Knowledge, Jason Wilson from the Curious About Cannabis podcast discusses with our host Evan Friedmann and guests TJ Martin, Ian Oswald, and Kyle Boyar, their experiences at the American Chemical Society (ACS) conference in San Diego. Wilson shares insights from a conversation with colleagues about their research on volatile sulfur compounds (VSCs) in cannabis, which contribute to its aroma. They found that while most VSCs were present in low concentrations, some strains like Gelato and GMO had higher levels. They also discussed the importance of proper packaging, noting that mylar bags can effectively retain these compounds. The conversation highlights the need for better analytical methods and open-access research to advance the cannabis industry. Link to Companion Curious About Cannabis Podcast Episode : https://cacpodcast.com/cannabis-quality-aroma-and-terpenes-what-do-we-really-know-with-tj-martin-iain-oswald-kyle-boyar-evan-friedmann/

Dioxin-like compounds can alter how white blood cells develop and do so in ways that current risk assessment methods fail to predict, according to a study from the Michigan State University Superfund Research Program Center.

Almost 500 child sextortion cases have been linked to scam compounds, Oracle's CSO departs after 37 years, Europol offers a reward for the Qilin ransomware group, and the UK drops its demand for an Apple backdoor. Show notes Risky Bulletin: NIST releases face-morphing detection guideline

In the aging brain, neurons begin to lose a hidden currency. Not just ATP, but GTP - that powers their ability to clear away toxic proteins. Without it, the cleanup crews stall, and amyloid builds up. A team at UC Irvine may have uncovered a way to recharge that system using two familiar compounds. In aged and Alzheimer's model neurons, this pairing restored GTP, reactivated trafficking pathways, and swept away protein aggregates. In this episode, we follow the trail from dwindling cellular energy to revived cleanup machinery, and explore how these findings fit with human evidence.00:00 Introduction: The Overlooked Clue in Aging Brains00:47 The Energy Crisis in Aging Neurons01:21 Natural Compounds to the Rescue01:55 The UC Irvine Study: A Closer Look03:05 Mechanisms Behind Nicotinamide and EGCG04:37 Human Data: What Do We Know?06:59 Comparing Strategies: Drugs vs. Natural Compounds08:11 Challenges and Future Directions09:27 Conclusion: A Promising but Unproven StrategyPMID: 40661491

Broadcast from KSQD, Santa Cruz on 8-14-2025: Dr. Dawn shares the story of Tim Fried, a construction worker who deliberately exposed himself to 850 snake venom doses over 18 years to build immunity. An immunologist developed antivenom from Fried's antibodies that neutralizes venom from 19 deadly snake species, potentially saving thousands of lives annually from snakebite deaths. She describes cuttlefish sign language research revealing four specific arm movements. The cuttlefish respond to videos and water vibrations from these signs, suggesting complex communication abilities rather than simple mimicry, potentially comparable to octopus intelligence. New research challenges the assumption that Neanderthals were hyper-carnivores. While bone nitrogen levels suggested a meat-only diet, dental evidence showed plant consumption. Researchers now theorize Neanderthals ate maggots from rotting meat, which contain 43% more nitrogen than flesh and would explain the contradictory evidence between bone chemistry and tooth wear patterns. CPR guidelines may soon from the traditional ABC approach (airway, breathing, circulation) to focusing immediately on chest compressions. Research on 45 collapsed athletes showed that 27 who received inappropriate airway clearing died or remained comatose, while three who received immediate rapid chest compressions survived with potential for rehabilitation. The recommendationcould become 100-120 compressions per minute without preliminary airway management. Dr. Dawn presents reassuring statistics about spinal abnormalities in pain-free adults over 60. MRI studies show 90% have disc degeneration, 80% have disc bulges, and 40% have protrusions - yet these individuals have no back pain. This raises questions about attributing back pain to imaging findings when so many similar abnormalities exist in asymptomatic people. Australian cockatoos have learned to operate drinking fountains for entertainment rather than necessity. Researchers observed 70 birds attempting and 40 successfully using fountains, waiting in organized lines and taking turns, despite easier water sources being available nearby. An emailer asks about Essiac tea for cancer prevention. Dr. Dawn explains this herbal blend of burdock root, Indian rhubarb, sheep sorrel, and slippery elm shows promise in laboratory studies but lacks quality human research. While not harmful, no studies demonstrate reduced cancer recurrence rates, though the antioxidant properties may provide general health benefits. Another emailer inquires about lithium supplements for Alzheimer's prevention. Dr. Dawn discusses research showing lower brain lithium levels in Alzheimer's patients and how amyloid plaques trap lithium. Studies suggest lithium orotate (unlike lithium carbonate) isn't absorbed by plaques and may help memory in mice. Low-dose lithium orotate appears safe and mildly calming for humans. Groundbreaking research shows exercise dramatically improves colon cancer survival. A study of 900 patients found the exercise group had 80% five-year disease-free survival versus 74% in controls, with 40% reduced death risk. The intensive program required 10 METs weekly exercise with behavioral support sessions over three years. Dr. Dawn explores coffee's health benefits, noting humanity consumes 2 billion cups daily. Multiple studies show moderate consumption (3-4 cups) reduces breast cancer risk in postmenopausal women and slows Parkinson's progression. Compounds like cafestol and chlorogenic acids provide anti-inflammatory and antioxidant effects, though benefits disappear when adding significant cream or sugar. She warns about Chikungunya outbreaks in China affecting over 8,000 people. This mosquito-borne illness causes severe bone pain and can spread through blood transfusion. With increased global travel and climate change expanding mosquito ranges, Dr. Dawn emphasizes the importance of volunteering travel history to healthcare providers when presenting with fever and body aches.

In this Huberman Lab Essentials episode, I explain how dopamine regulates motivation and provide science-based tools to help improve focus, discipline and overall drive. I explore how particular activities affect dopamine levels and discuss how the highs, lows and baseline levels of dopamine shape your motivation and long-term satisfaction. I also explain practical strategies to boost dopamine levels, such as deliberate cold exposure, caffeine, effort-based rewards and specific supplements. Whether you're looking to enhance motivation for school, work or daily life, this episode explains how to get and stay motivated while supporting healthy dopamine levels. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman LMNT: https://drinklmnt.com/huberman David: https://davidprotein.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00) Dopamine & Drive (00:33) Neuromodulators; Dopamine Effects, Parkinson's Disease; Brain Circuits (03:36) Motivation & Dopamine Levels (04:55) Sponsors: AG1 & LMNT (07:29) Subjective Experience & Dopamine, Activities that Increase Dopamine (10:55) Dopamine Highs, Lows & Baseline; Evolutionary Context, Addiction (16:16) Dopamine Reward Prediction Error, Tool: Intermittent Rewards (18:16) Caffeine & Dopamine; Tool: Yerba Mate & Protecting Dopamine Neurons (19:40) Sponsor: David (20:53) Amphetamine, Cocaine & Challenges for Learning (22:22) Tool: Increase Dopamine & Deliberate Cold Exposure (25:06) Hard Work & Motivation, Intrinsic vs Extrinsic Rewards, Tool: Growth Mindset (30:25) Sponsor: Function (32:04) Experiences & Shifting Perception, Dopamine Balance (33:17) Compounds to Increase Dopamine: Wellbutrin, L-Tyrosine, PEA, Alpha-GPC (36:54) Social Connection; Recap & Key Takeaways Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Dr. Andy Cutler interviews Dr. Pamela Wall about the complex intersection of PTSD and mild traumatic brain injury (mTBI) in veterans. They explore how military culture influences the experience and treatment of trauma, the challenges of distinguishing overlapping symptoms, and evidence-based strategies for assessment and intervention. Tune in for practical insights, clinical pearls, and resource recommendations for improving care in this uniquely vulnerable population.  Pamela Wall, PhD, PMHNP-BC is an associate professor in the College of Nursing at Rosalind Franklin University and maintains a clinical practice at a neuropsychiatric clinic in Fairfax, VA. She has extensive experience working with adult psychiatric mental health populations, and her research has focused on PTSD, mTBI, and sleep disorders in deployed military service members. Dr. Wall served 20 years on active duty as a Nurse Corps Officer in the United States Navy.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Center for Deployment Psychology   National Center for PTSD  Traumatic Brain Injury Center of Excellence    Never miss an episode!

Today we speak to investigative journalists Nathan Paul Southern and Lindsey Kennedy. We talk about the recent clashes on the Thailand - Cambodia border and how they might be linked to a shadowy scam network... No ads and tons of exclusives: www.patreon.com/popularfront Kevlar vest fundraiser: https://www.gofundme.com/f/kevlar-for-khmer-journalists Discounted internet privacy for all our listeners: proton.me/popularfront - Info: www.popularfront.co - Merch: www.popularfront.shop - News: www.instagram.com/popular.front - Jake: www.jakehanrahan.com

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com0:00 – Intro1:55- Prep vs Off-Season Diet4:56 – Stretching before the show6:55 - Dubai Pro Success9:40 – Switching to Machines12:07 – Dealing with Personal Issues15:45 – Coaching Myself17:52 – Stomach Issues & Solutions23:52 – Cutting Compounds Early27:25 – Working with Patrick29:38 – Trusting My Instincts34:00 – Improving Lats41:02 – Leg Training Insights44:39 – Reverse Grip for Lats45:35 – Using Drop Sets & Intensifiers53:34 – GLP-1 & Digestion Concerns1:08:30 – Secrets to Insane Conditioning1:13:20 – Making Weight for Shows1:21:00 – Moderate Peak Week Philosophy1:23:30 – Gradual Carb Increase Strategy1:38:43 – Michaels's Favourite Off-Season1:40:35 – High Doses, No Gains1:49:30 - Compounds that didn't work for Michael1:54:50 – Financing Bodybuilding as a Pro1:59:38 - Mindset is everything2:04:50  - Most important supplements2:07:00 – Final Message to the World

In Part 7 of our Sales Culture Series, we're talking about what really drives long-term success: consistency. From systems and onboarding to daily habits and mindset shifts, this episode breaks down how to build a culture where production compounds.#StateFarmAgent #InsuranceAgent #StateFarm #TMP #TeamMemberPerspective #SalesCulture #FinancialServices #AgencyGrowth #LifeInsurance #SalesTraining✅ Questions about enrolling your team in our Friday Live Training & Wednesday Live Role Play Calls? Click Here: http://sales.tmperspective.com-✅ Subscribe to Colter's FREE insurance sales trainings:Youtube: https://www.youtube.com/channel/UC-35rEOirer-rBo62SAokawApple Podcasts:⁠https://podcasts.apple.com/us/podcast/the-team-member-perspective/id1675925320⁠Spotify:⁠https://open.spotify.com/show/0EYYJYvouM22DfuAcYjhiK?si=m8gTTwvFReGfSIGQ7yZHcQ⁠Private Facebook Group: https://www.facebook.com/share/g/sSe3faCfV6KLVJh4/

Every once in a while we are lucky to enough to be able to speak to a true hip-hop legend, and today is one of those occasions. Dad Bod Rap Pod hosts David Ma, Demone Carter and Nate LeBlanc are thrilled to be talking to and about Lord Finesse on this week's episode. Lord Finesse made three highly influential albums as an artist in the 90's and continues to impact the culture as a respected DJ and producer today. He is here to promote his latest album The SP1200 Files: Sounds & Frequencies In Technicolor. We caught up with Ness in his studio where he was busy working on remastering his classic debut The Funky Technician. As always, we also dive into his history, we think even a dedicated DITC head will learn something new from this interview. An extended version of this episode, along with hundreds of hours of bonus commentary, playlists, mixes, and a thriving community of rap nerds is available on our patreon: www.patreon.com/dadbodrappod DBRP is brought to you by Stony Island Audio.

DNS 275 Dave Crosland & Scott McNally 0:00 teaser clip 0:20 Intro and advertisers 2:00 Suck it England! 3:40 Masters Cycles 11:50 Raw Powder Supply Chain Update 18:45 Compounds for the 3D look? 21:50 Will GLP meds take away the achievement of condition? 31:45 Lifetime Natty First Cycle? 34:00 Multiple Pathways on Cycle 37:40 GH Releasing Peptides 40:20 Does T3 Burn Muscle? 43:16 Correcting Constipation 46:05 Cycle Proposal 47:15 Adding Exogenous Estrogen to Cycles? 51:15 BP Meds? 53:00 Gear that is most damaging to male fertility 54:30 Cycle Proposal for Off Season with 1g test 56:25 SS31 Update 59:00 Correcting Low SHBG 1:00:45 Correcting Joint Pain 1:07:45 Infection or Allergic Reaction? 1:11:15 Best Fish and Chips by Dave 1:13:00 Strom SupportMax

Most people confuse success with excellence. But they're not the same. In this episode, John Eades shares the story of how British Cycling transformed from mediocre to dominant, unpacks why Joe Burrow's post-game comments reveal the mindset of a high performer, and breaks down The Excellence Loop—a four-step framework to help you lead, work, and live with a higher standard. Quote of the Day: “Success is what you get. Excellence is what you become.”

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Brian Kennedy is a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. In this episode, Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives. We discuss: Brian's journey from the Buck Institute to Singapore, and the global evolution of aging research [2:45]; Rethinking the biology of aging: why models like the hallmarks of aging fall short [9:45]; How inflammation and mTOR signaling may play a central, causal role in aging [14:15]; The biological role of mTOR in aging, and the potential of rapamycin to slow aging and enhance immune resilience [17:30]; Aging as a linear decline in resilience overlaid with non-linear health fluctuations [22:30]; Speculating on the future of longevity: slowing biological aging through noise reduction and reprogramming [33:30]; Evaluating the role of the epigenome in aging, and the limits of methylation clocks [39:00]; Balancing the quest for immortality with the urgent need to improve late-life healthspan [43:00]; Comparing the big 4 chronic diseases: which are the most inevitable and modifiable? [47:15]; Exploring potential benefits of rapamycin: how Brian is testing this and other interventions in humans [51:45]; Testing alpha-ketoglutarate (AKG) for healthspan benefits in aging [1:01:45]; Exploring urolithin A's potential to enhance mitochondrial health, reduce frailty, and slow aging [1:05:30]; The potential of sublingual NAD for longevity, and the combination of NAD and AKG for metabolic and exercise enhancement [1:09:00]; Other interventions that may promote longevity: spermidine, 17

Benji explains how Pump Science leverages blockchain and cryptocurrency to revolutionize the search for longevity supplements. By using an automated, standardized process, Pump Science efficiently funds research and collects robust data to accelerate the discovery and validation of effective supplements for extending healthspan

Watch Here : https://www.youtube.com/watch?v=eI1Y7IFENIo Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

“Just avoid wine and cheese!”If only it were that simple.Welcome back to The Migraine Heroes Podcast, where we explore the real reasons behind your attacks and how to stop them. Hosted by Diane Ducarme, who's helped over 500 women get their lives back, this podcast blends the best of neuroscience with the deep-rooted wisdom of Traditional Chinese Medicine.In today's episode, we unpack the controversial world of tyramine and histamine—two compounds that hide in your favorite foods and may be secretly fueling your migraine attacks.You'll learn:Why fermented, aged, or even slightly spoiled foods can create a “perfect storm” in your brainWhat tyramine and histamine actually do to your nervous system, and why some bodies just can't process them wellHow medications like NSAIDs, antidepressants, and even common antibiotics can interfere with the body's ability to break down histamine making migraine triggers themselves (!)How to build a path back to food freedom—without fearWhether you've been told to cut all histamine-rich foods or you've noticed wine, cheese, or avocado leave you foggy and drained, this episode is your science-backed, heart-centered guide to understanding why—and what to do next.

TRT Clinic Cycles : What Compounds are legally available? Benefits of Test Gel and Transdermal Gear, Deca & Dopamine, Controlling Hematocrit -DNS Podcast 269 - Dave Crosland & Scott McNally 0:00 Intro and Sponsors 0:55 Best Gear You Can Get From Your Doctor? 1:30 What Is Proviron Prescribed For? 2:30 Compounds from US Compounding Pharmacy 6:00 How high dose is Testosterone Prescribed? 11:25 Prescription Dosing of Anavar and Winstrol 12:00 Deca Dosing by Prescription 14:30 Over the Counter Insulin 16:30 Retatrutide VS Semaglutide 24:30 Transdermal Testosterone 26:45 Test Gel To Get Hematocrit Down 28:45 ADHD Meds and Nandrolone 31:15 Deca and dopamine 33:25 methylene blue & cabergoline 34:00 Pain from EQ shots? 35:00 Getting Labs that qualify for TRT 38:00 Shut Down From Deca 42:00 Testing EQ as an Ai 43:00 Bringing down hematocrit 47:40 How much bacteriostatic water to add to BPC and how to dose it ?52:30 Dave's Car talk + Uncle Dave's Wisdom

Want to learn more about investing in real estate? Visit https://www.therealestateinvestingclub.comInterested in investing in my projects? Visit https://www.kaizenpropertiesusa.comTHE ANTI-MULTIFAMILY STRATEGY: WHY INDUSTRIAL IS KING

In this edition of Between Two Nerds Tom Uren and The Grugq discuss the Southeast Asian criminal syndicates that run online scam compounds. Should organisations like US Cyber Command or the UK's National Cyber Force target these gangs with disruption operations? This episode is also available on Youtube. Show notes UN Office of Drugs and Crime on Southeast Asian transnational cyber scammers

In celebration of our 200th episode, this conversation highlights 20 key lessons we've learned over the past five years of hosting this podcast. Join us as we take a deep dive into leadership philosophy, drawing from insights we've gathered since the very beginning. You'll hear what it means to lead from the front, why going viral isn't necessary to make an impact, and how building character shapes everything you do. We also unpack the recent drop-off rate in the real estate world and explore how a strong sense of purpose can fuel perseverance. As we reflect on the growth that comes with each new season, we invite you to consider your own journey. Whether you're tuning in for the first time or you've been with us since the start, this episode will inspire you to move from reflection to action. Thanks for being part of the journey!Key Points From This Episode:•   Taking action beyond thinking and reflection. •   The critical role of trust and what happens in a crisis without it.•   Why curiosity is a leadership superpower.•   The little things that build your character. •   Understanding the role of purpose. •   Taking advantage of the opportunity for growth that each new season brings. Quotes:“Start before you feel ready.” — BJ Kraemer  “Repetition builds your repetition.” — BJ Kraemer  “You can't lead well if you don't listen first.” — BJ Kraemer “People will listen to what you say but they're going to watch what you do.” — BJ Kraemer “The best seasons are the ones where you're growing.” — BJ Kraemer Links Mentioned in Today's Episode:Leadership Blueprints PodcastMCFAMCFA CareersBJ Kraemer on LinkedIn

Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

Could a class of drugs that clear aging cells also help treat Alzheimer's disease? A recent study, featured as the cover for Aging (Volume 17, Issue 3), titled “Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer's disease,” suggests they might—and with remarkable precision. Understanding Alzheimer's Disease Alzheimer's disease is a progressive neurological disorder that gradually steals memory, independence, and a person's sense of identity. A defining feature of Alzheimer's is the buildup of amyloid-β (Aβ) plaques—sticky protein clumps that interfere with communication between brain cells. This disruption is closely linked to changes in a group of enzymes called cholinesterases, especially acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These enzymes normally play a vital role in regulating neurotransmitters critical for memory, learning, and cognitive function. In Alzheimer's, however, their behavior changes significantly, particularly when they interact with Aβ plaques. The Study: Exploring Senolytics for Alzheimer's Enzyme Inhibition A research team from Dalhousie University in Canada looked into whether senolytic compounds—a class of drugs that eliminate damaged, aging cells often referred to as “zombie” cells—could also target the harmful forms of cholinesterase enzymes found in Alzheimer's disease. Their goal was to see if these compounds could selectively inhibit the disease-associated versions of AChE and BChE, without affecting the healthy forms that are essential for normal brain function. Full blog - https://aging-us.org/2025/04/senolytic-compounds-show-promise-in-targeted-alzheimers-treatments/ DOI - https://doi.org/10.18632/aging.206227 Corresponding author - Sultan Darvesh - sultan.darvesh@dal.ca Video short - https://www.youtube.com/watch?v=CJQFpG9Jn6Y Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206227 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, β-amyloid, acetylcholinesterase, butyrylcholinesterase, cholinesterase inhibitors About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

AP correspondent Charles de Ledesma reports the death toll in last week's massive earthquake in Myanmar has passed 2,000, as rescuers and an activist group say it killed hundreds of Muslims and Buddhist monks.

Welcome to Episode 216 of Pelo Buddy TV, an unofficial Peloton podcast & Peloton news show. This week we cover the following topics: Peloton is rolling out some changes to their class schedule. Both PSL and PSNY will be closed for maintenance soon. You can now search for specific collections & programs in the Peloton app. Tunde Oyeneyin has a new 4-week upper body strength program. Rebecca Kennedy has a new “Compounds and Core” Strength+ Program. A Lady Gaga artist series took place this week Peloton highlighted several classes in their “This Week at Peloton” post. Christian Vande Velde will be back at Peloton teaching classes April 18-20. The third lululemon members weekend will be June 20 – 22 at PSNY. Joslyn Thompson Rule will take part in a virtual panel that anyone can watch. Susie, Erik, and Jeffrey will host a shakeout run in Berlin next month. Peloton devices are on sale in Amazon in the US, and the Peloton website in other countries. Peloton recently closed 4 more of their showrooms in the US. Happy Birthday to Becs Gentry this week Susie Chan taught a 2 hour run Rad Lopez had his premiere bike bootcamp class. Mariana Fernandez spoke at Bloomberg. Adrian Williams is one of the pacers of the lululemon 10K in Miami. Camila Ramon is teasing some new projects. Ally Love was interviewed by Bobbi Brown. Class Picks of the Week Enjoy the show? Become a Pelo Buddy TV Supporter!  Find details here: https://www.pelobuddy.com/membership-account/membership-levels/ You can find links to full articles on each of these topics from the episode page here: https://www.pelobuddy.com/pelo-buddy-tv-episode-216/ The show is also available via YouTube: https://www.youtube.com/c/PeloBuddy This episode is hosted by Amanda Segal (#Seglo3) and John Prewitt (#Kenny_Bania).

Astronomy Daily | Space News: S04E72In this action-packed episode of Astronomy Daily, host Anna takes listeners on a journey through the latest groundbreaking discoveries and developments in space exploration. From revolutionary findings by NASA's Curiosity rover on Mars to the implications of colossal black hole eruptions, this episode is filled with cosmic revelations that will leave you eager for more.Highlights:- Curiosity's Organic Discovery on Mars: Discover how NASA's Curiosity rover has identified the largest organic compounds ever found on the Martian surface, including significant fatty acids that could hint at the planet's potential for past life. This discovery opens new avenues in our understanding of Martian organic chemistry and its implications for life beyond Earth.- A Surge in Rocket Launches: Join us as we discuss the whirlwind of recent rocket launches, including SpaceX's classified missions and Isar Aerospace's historic attempt to launch the first European rocket from continental Europe. With numerous launches scheduled, the commercial space sector is witnessing an unprecedented surge in activity.- Webb Space Telescope's Stunning Observations: Marvel at the James Webb Space Telescope's latest findings, which reveal a cosmic alignment of two unrelated objects, challenging previous assumptions about star formation and the universe's structure. This stunning imagery underscores Webb's ability to reshape our understanding of cosmic phenomena.- Alarming Black Hole Discoveries: Explore the terrifying implications of a newly detected supermassive black hole producing enormous jets stretching six million light years. This revelation raises critical questions about galactic evolution and the potential dangers posed by black holes, including their effects on our own Milky Way.- Progress on NASA's Artemis Program: Get the latest updates on NASA's Artemis 2 mission, which aims to return humans to deep space. With significant milestones achieved, the mission is on track for a potential launch next year, marking a historic moment in human space exploration.For more cosmic updates, visit our website at astronomydaily.io. Join our community on social media by searching for #AstroDailyPod on Facebook, X, YouTubeMusic, TikTok, and our new Instagram account! Don't forget to subscribe to the podcast on Apple Podcasts, Spotify, iHeartRadio, or wherever you get your podcasts.Thank you for tuning in. This is Anna signing off. Until next time, keep looking up and stay curious about the wonders of our universe.00:00 - Welcome to Astronomy Daily01:05 - Curiosity rover's organic compounds discovery10:30 - Recent rocket launches and advancements17:00 - Webb Space Telescope's cosmic observations22:15 - Erupting black hole findings27:30 - Updates on Artemis 2 mission progress✍️ Episode ReferencesCuriosity Rover Findings[NASA](https://www.nasa.gov)Rocket Launch Updates[SpaceX](https://www.spacex.com)James Webb Space Telescope Observations[NASA](https://www.nasa.gov/webb)Supermassive Black Hole Research[Astrophysical Journal](https://iopscience.iop.org/journal/0004-637X)Artemis Program Updates[NASA Artemis](https://www.nasa.gov/specials/artemis/)Astronomy Daily[Astronomy Daily](http://www.astronomydaily.io/)Become a supporter of this podcast: https://www.spreaker.com/podcast/astronomy-daily-space-news--5648921/support.

We are very excited to welcome Brandon from Future Compounds to the show! Future Compounds makes CBD and CBG products, providing a fantastic product for a very fair price. Check them out at https://futurecompounds.com

Truth about steroids - The largest convicted steroid dealer in US history. Ryan is a biochemist, who tailored his degree, and the last 20 years of his life, to understanding and studying these compounds with over two decades of experience in the hormone industry. He discusses his story, problems with UGL and how steroids and the industry have changed in the last decade.Watch it: https://youtu.be/SsIC4dQQxyM?si=NpEjXAaDsykN2Wz2Join the Bodybuilding-friendly HRT Clinic - Get professional medical guidance on your health as a bodybuilder:[ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaPlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00 Intro  03:19 Biggest Fear of a Solo Podcaster  08:22 Ryan's Steroid Empire  08:50 Ryan Guiding People  10:00 Ryan's Early Life & Struggles  15:35 How Ryan Got into Studying Steroids  17:22 Ryan's First Source  19:33 Were Steroids Better Back Then?  22:52 How Ryan Got into Online Selling  29:54 Ryan's Business Model Back Then  33:27 Ryan's Routine When the Empire Was Rising  36:38 Helping People  38:49 Growing The Business  46:00 Reviews that Ryan Got  49:09 The Hardest Compound to Make  53:10 Making His Own Stuff  55:33 How Ryan Got Caught First  1:00:06 Operation Cyber Juice  1:07:55 Prison And People  1:12:42 Government's View on Substances Then vs Now  1:17:52 Politics Behind Steroids  1:26:46 Big Pharma, Lobbyists & Hidden Agendas  1:28:43 Testosterone is a Cure?  1:35:43 How Bad Science Shaped Public Perception  1:40:10 Different People, Different Results  1:42:58 Self-Centricity  1:49:34 Faking is Not Needed Anymore  1:53:49 Would Ryan Do It Again?  2:00:52 Keep it Simple  2:04:02 Do Lot of People Secretly Take PEDs? Ryan's View  2:05:43 Most Selling Compound After Test  2:07:15 Higher Doses, For Longer Time = Issues?  2:11:14 Heart Murmurs and Compounds  2:12:52 Preventing Hypogonadism  2:17:05 Prison Life  2:17:37 The Problem with The Justice System  2:20:33 Benzyl and Solvents in UGL Gear  2:23:40 The Final Question  2:25:17 The End  

In this podcast Tom Uren and Patrick Gray discuss how Starlink is providing an internet lifeline for scam compounds that have had their internet access cut by Thai authorities. Starlink has a very poor track record dealing with unauthorised use, but it is time for the company to develop the processes to keep on top of these problems. They also discuss how President Trump's actions that favour Russia will make Five Eyes partners take stock, particularly when it comes to HUMINT intelligence sharing. Finally they examine the did-it-happen-or-not stand-down of US Cyber Command's Russian operations. This episode is also available on Youtube. Show notes

#372: Consistency compounds!!

Coach Scott McNally - Ask Me Anything! Scott has been coaching full time for the last decade and is here to share the same tactics he brings to his clients. Reach out to Scott for Coaching : mcnallydiets@gmail.com (time stamps may be slightly off) 0:00 Preamble 5:00 Get multiple perspectives to help shape your own our perspective 6:45 6 month prep to Tampa Pro 10:45 Injectable Dbol Dosing vs Oral Dbol 14:45 My SLU-PP-332 Update 16:00 Is there fake SLU floating around? 18:00 Holding scale weight 25:00 Austin's before pics 28:15 Remember GH15? 30:00 How frequent can you use an injection site? 34:40 GH during TRT phases 37:00 Low T4 on Growth Hormone 38:35 Rest time between sets 44:45 is MENT (Trestalone) great mass builder or not worth the sides? 48:30 Over the counter sups to avoid post workout 52:30 Is there no need for anything more than 300 test in a cycle? 55:00 Cosmetic effect of EQ 56:20 Welcome Christmas Cabbage 57:00 Summer ready cycle vs contest prep 59:00 Sam Sulek and new school bodybuilders 1:05:40 340 lbs and looking for a cycle 1:11:45 Costco or Sams Club 1:12:30 Free Test or Total Test - Whats most important? 1:14:15 First Cycle 1:20:40 Advice for First Contest 1:23:00 Compounds for females 1:26:45 Winstrol for off season? 1:28:30 Fighting winter as a bodybuilder Immune System Building - Vitamin D, Red Light, Hydration, Electrolytes 1:36:45 Addiction - 17 years clean!! 1:40:45 B12 injections vs Sublingual

The detailing industry is packed with myths, marketing gimmicks, and straight-up misinformation—especially when it comes to compounds and polishes. What actually works, and what's just marketing hype? In this first part of our deep dive, we're exposing the secrets they DON'T want you to know! This episode is all about cutting through the BS and getting real results. Whether you're a pro detailer or a weekend warrior, this is one you don't want to miss! This episode isn't just about breaking down the truth behind compounds and polishes, but also testing a new potential product for Jimbo's Detailing to see if it holds up in real-world conditions. Buy Jimbo's Detailing Products here: https://JimbosDetailing.com or on Amazon https://amzn.to/3Wpoq93 CONNECT WITH JIMBO: INSTAGRAM: https://www.instagram.com/jimbobalaam/ PODCAST: http://www.AutoDetailingPodcast.com FACEBOOK: http://www.Facebook.com/AutoDetailingPodcast or http://www.facebook.com/jimbo.balaam

TIME STAMPS BELOW - Scott McNally learns about SLU-PP-332, Dave Crosland's Labs Leading Into Kidney Failure, Managing Estrogen on Dbol, Frequency with Long Esters, High DHT Cycles vs Old School, Supplements to Lower SHBG & Which One Is Pudding? DNS Podcast 254 0:00 Introduction and Sponsors 1:30 Discussion on SLU PP 332: A New Fat Loss Agent 3:10 Scott Sets a Personal Goal 5:08 Mechanism of Action and Potential Results 6:10 Metabolic Syndrome and Potential Benefits of SLU-PP-332 9:15 Scientific Studies and Evidence on SLU P P332 11:00 Dave's Experience with Kidney Issues and Blood Work 17:30 Blood Work Is Not The Complete Story 20:45 Cardiovascular Health and Exercise Considerations 21:50 Be Cautious with "New" Compounds 24:50 Managing Estrogen Especially on Dbol 31:45 Injection Frequency for Long Esters 37:00 Recovery and Management of Injuries 41:00 High-Dosage DHT Off Season Cycles 46:00 Metformin & Telmisartan 47:45 Low Dose Cycles for an Average Gym-Goer 53:00 Gear for hernia recovery ? 54:10 Supplement Choices for Lowering SHBG 57:30 Discussion on GKU Copper and Skin Tightening 1:00:10 Which one is pudding? Which is a Dinner Roll? 1:03:00 Dave's Dog, named Pudding 1:03:40 Uncle Dave's Advice 1:05:40 Dave going to Japan 1:09:00 Super Prison with drones in UK

This week George discusses the power of Cruciferous vegetables and the prized antioxidants I3C and DIM. Cruciferous vegetables and I3C and DIM compounds provide support like no other food on the planet.He also discusses Female Plus: New Formula for Hormone Balance, Energy, and Vitalitywww.georgebatista.comwww.myvitaminresource.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sana announces beta cell transplantation without the need for immunosuppresion drugs, Modular Medical teams up with Nudge BG for a brand new completely closed-loop system, the FDA moves forward to crack down on compounded Ozempic and Mounjaro, Dexcom and Abbott bury the legal hatchett for a while, and more.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Big news from Sana Biotechnology. Their first in human study of islet cells without any immunosuppression appears to be a success. This is very early and hasn't yet been peer reviewed and published.. but after four weeks, there were no safety issues and the transplanted beta cells were producing insulin. Sana's CEO says  “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases.”   I've reached out to Sana to get more on this.. love to talk to them soon.   https://www.bakersfield.com/ap/news/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-cell/article_d0390fd6-99cb-53bd-b04d-9337121e01bf.html XX FDA says no for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).  Studies showed a meaningful reduction in A1C but a meaningful increase in DKA. The FDA first rejected this in 2019 and was resubmitted last summer. But The advisory committee voted 11 to 3 against the approval of sotagliflozin stating that the benefits of sotagliflozin do not outweight the risks in adults with T1D and CKD. Sotagliflozin is currently approved under the brand name Inpefa to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with 1) heart failure; or 2) type 2 diabetes mellitus, CKD, and other cardiovascular risk factors.  According to Lexicon, Inpefa will continue to be manufactured and made available to patients. https://www.renalandurologynews.com/news/fda-denies-approval-of-zynquista-for-type-1-diabetes-and-ckd/ XX Two companies we've been following are teaming up.. Modular Medical has an FDA clear patch pump and Nudge BG has an adaptive full closed loop. They've announced a new partnership agreement. From the release: Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor." Familiar name to some of you, Lane Desborough is the founder of Nudge BG. He says this will be a fully automated system, no mealtime bolusing needed.   https://www.accesswire.com/957703/modular-medical-announces-licensing-and-partnership-agreement-with-nudge-bg XX Beta Bionics filed for an initial public offering on Monday. The company did not disclose the number of shares it will offer or the price range. Beta Bionics plans for shares to be listed on the Nasdaq under the ticker symbol “BBNX.” The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device.   https://www.medtechdive.com/news/beta-bionics-insulin-pump-files-ipo/736805/     XX Tandem Diabetes Care, Inc. signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.   There's a long history here – UVA is where the Control IQ algorithm was developed.  This agreement seems to keep the team together for another decade. https://www.businesswire.com/news/home/20250107162995/en/Tandem-Diabetes-Care-Enters-Multi-Year-Research-Collaboration-with-UVA-Center-for-Diabetes-Technology-for-Development-of-Advanced-Insulin-Delivery-Systems XX New study says insulin is still the best treatment for gestational diabetes, compared to oral glucose-lowering medications. Metformin and gluburide are being closely looked at since they're easier to administer, less costly, and have better acceptance among patients. But this study says insulin was a bit better – slight more babies were born larger for the metformin group, and more moms had hypoglycemia. https://www.medpagetoday.com/obgyn/pregnancy/113651 XX In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza. Novo Nordisk last month filed a Citizen Petition with the FDA asking the federal agency to exclude its type 2 diabetes injection Victoza (liraglutide) from a proposed list of drugs eligible for compounding. https://www.biospace.com/fda/novo-launches-citizen-petition-to-block-compounded-victoza XX Bit of an update on compounded terzepatide and semaglutide. The FDA is allowing a grace period of 60 days before starting to enforce the end of allowing compounds of Mounjaro. Meanwhile, semaglutide remains on the FDA's shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024. Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet  the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands.   https://www.drugdiscoverytrends.com/compounders-and-drugmakers-clash-over-compounded-weight-loss-drugs-with-fda-in-the-middle/ XX Interesting story here.. this study says a fecal transplant can help people with type 1 and severe gastroenteropathy. The researchers say diabetic gastroenteropathy commonly affects individuals with type 1 diabetes, causing debilitating symptoms like nausea, vomiting, bloating, and diarrhea; however, treatment options remain limited. Researchers conducted a novel clinical trial to test the benefits of FMT in adult patients with type 1 diabetes and severe symptoms of gastroenteropathy, who were randomly assigned to receive either FMT or placebo capsules as the first intervention. After four weeks, Compared with placebo, FMT led to significant changes in the diversity of the gut microbiome. https://www.medscape.com/viewarticle/fmt-shows-early-success-type-1-diabetes-bowel-issues-2025a10000bg XX A couple of weeks ago, listeners told me that the Dexcom geofencing issue we reported on seems to be resolved. Dexcom is now confirming this. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. As of last month, the geofencing issue has now been resolved with the latest Dexcom G7 2.6 app update. Can I travel with my Dexcom G7? | Dexcom XX Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years.   Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits. https://www.medtechdive.com/news/abbott-dexcom-settle-cgm-patent-lawsuits/736300/  

As more research and data comes out around stress and the role it plays within our health and fitness, the more we need to educate our clients on it's impact and provide them with tools and strategies around stress management. In today's episode, I want to dive into the impact that chronic stress has on both our physiology and psychology, perceived stress, supplementation considerations, and more. Topics include:   - The Process of Chronic Stress - Please Share, Rate, and Review - The Psychological and Physiological Connection - Perceived Stress - Chronic Stress and Brain Function - Supplementation/Vitamin Considerations - Other Content Around Stress     ----------  My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization  www.metabolismschool.com ----------  Subscribe to My Youtube Channel:  https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1 ----------   [Free] Metabolism School 101: The Video Series http://www.metabolismschool.com/metabolism-101 ----------   Grab a Copy of My New Book - Metabolism Made Simple ----------   Stay Connected:   Instagram: @sammillerscience   Youtube: SamMillerScience   Facebook: The Nutrition Coaching Collaborative Community   TikTok: @sammillerscience       ---------- “This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at team@sammillerscience.com. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

Kimchi and sauerkraut are 2 of the top probiotic foods. Both are made of fermented cabbage. Sauerkraut has a mild taste, while kimchi is spicy and contains other vegetables. Kimchi is made from napa cabbage, radish, garlic, chili pepper, ginger, and salt. Because kimchi contains more vegetables, it has more phytonutrients. It also has a higher diversity of microbes. The dominant microbe in sauerkraut and kimchi is Lactobacillus plantarum. It can survive harsh environments, including the acid in your stomach. This microbe contributes to beneficial gut bacteria and can also increase serotonin. Kimchi helps cultivate a unique microbe not found in sauerkraut that inhibits pathogens such as listeria. It's also protective against fungus, yeast, and mold. Sauerkraut has more of the microbe L. brevis, which benefits gut health and the immune system. Sauerkraut and kimchi both make bacteriocins, which are natural antibiotics. Sauerkraut and kimchi are both made of fermented cabbage, a cruciferous vegetable with the following beneficial properties: •Rich in phytonutrients •Loaded with glutathione •Contains anthocyanins that support longevity •Potent source of vitamin U, which protects against ulcers •Contains glutamine, which is very beneficial for a leaky gut Not only does kimchi have more diverse microbes, but it also contains fermented garlic, which has potent antimicrobial, antioxidant, and anti-inflammatory effects. It's also very beneficial for your immune system. There's a compound in ginger that turns into several other anti-inflammatory molecules when fermented. Ginger is beneficial for digestion and can be an effective remedy for nausea. Compounds in chili pepper are also enhanced when fermented and are beneficial for pain, inflammation, circulation, metabolism, and fat loss. Kimchi is better for weight loss because of its beneficial properties for blood sugar and insulin resistance. It also has more vitamin C. Look for raw sauerkraut or kimchi for the most benefits!

DON MOXLEY is the Sport Science Director at Stemregen, a leader in stem cell science-backed supplements. Driven by a personal mission to help people make necessary changes to alleviate suffering and enhance the well-being of all, he leverages his experience as an athlete, sports scientist, and educator to advance human performance and longevity. Whether he's sharing insights on a podcast, presenting cutting-edge research on stem cells and performance at a wellness conference, or offering practical advice on living an active and fulfilling life, Don makes the science of stem cells and longevity both accessible and actionable.  A former captain and Big Ten Champion with the Ohio State University wrestling team, he also served as the university's first sport scientist. He helped athletes track their progress in strength, cardiovascular fitness, and resilience training, leading to the team's national title and three Big Ten Championships. Throughout his career, Don has guided athletes to remarkable success, including two Olympic medals, four World Championships, seven National Championships, and 23 All-American honors.   Work With Me: Mineral Balancing HTMA Consultation: https://www.integrativethoughts.com/category/all-products  My Instagram: @integrativematt My Website: Integrativethoughts.com   Advertisements:   Viva Rays: Use Code ITP for a Discount https://vivarays.com/   Zeolite Labs Zeocharge: Use Code ITP for 10% off https://www.zeolitelabs.com/product-page/zeocharge?ref=ITP Magnesium Breakthrough: Use Code integrativethoughts10 for 10% OFF https://bioptimizers.com/shop/products/magnesium-breakthrough Just Thrive: Use Code ITP15 for 15% off https://justthrivehealth.com/discount/ITP15 Therasage: Use Code Coffman10 for 10% off https://www.therasage.com/discount/COFFMAN10?rfsn=6763480.4aed7f&utm_source=refersion&utm_medium=affiliate&utm_campaign=6763480.4aed7f   Chapters: 00:00 Introduction to Don Moxley and StemRgen 05:53 The Role of Stem Cells in Recovery 15:02 The Importance of Staying Active 20:20 The Science Behind Stem Regen 28:37 Exogenous Stem Cells vs. Natural Supplements 35:21 The Power of Hyperbaric Therapy 40:37 The Importance of Longevity and Vitality 49:18 Exploring Stem Cells and Their Applications 56:01 The Importance of Micronutrients 01:01:19 Personalized Health and Optimization   Takeaways: HRV is a crucial indicator of recovery and performance. Stem cells play a vital role in the body's healing process. Aging leads to a decline in stem cell production. Staying active is essential for longevity and health. Stem Regen can enhance the body's natural healing abilities. Exercise stimulates the release of beneficial molecules like BDNF. Natural supplements can be more accessible than exogenous stem cell treatments. Maintaining a healthy lifestyle can improve overall well-being. The body responds better to gradual increases in stem cell circulation. It's important to be cautious with supplements and their certifications. Hyperbaric therapy can provide significant relief from chronic pain. STEM Regen protocol led to a rapid recovery from knee pain. Inflammation is a major barrier to healing and performance. Longevity is about feeling good and being active at any age. Hormone replacement therapy can be a natural part of health optimization. Nutrition quality is often compromised in industrial food production. Personalized health strategies are essential for optimal performance. Micronutrients play a critical role in cellular health and recovery. Understanding your body's needs is key to thriving as you age. Supplementation can help address deficiencies in modern diets.   Summary: In this conversation, Matthew Coffman interviews Don Moxley, an expert in exercise physiology and stem cell research. They discuss the importance of heart rate variability (HRV) as a key performance indicator for health and recovery, the role of stem cells in healing and recovery, and how aging affects stem cell production. Moxley shares insights on the benefits of staying active and the significance of supplements like StemRgen in enhancing recovery and performance. The discussion also touches on the differences between exogenous stem cells and natural supplements, emphasizing the importance of a holistic approach to health and wellness. In this conversation, Don Moxley shares his personal journey of overcoming significant health challenges, including a serious knee injury and subsequent MRSA infection. He discusses the transformative effects of hyperbaric therapy and the STEM Regen protocol, which helped him regain mobility and reduce inflammation. The conversation also delves into the importance of longevity, hormone replacement therapy, and the role of nutrition in optimizing health and performance. Moxley emphasizes the need for personalized health strategies and the significance of micronutrients in achieving overall well-being.  

Energetic Health Institute Radio with Jolene Goring, CHN – Pain often stems from inflammation, injury, or tension. While pharmaceuticals mask symptoms, natural alternatives often address root causes, providing relief while supporting the body's healing processes. Compounds in certain foods, herbs, and practices can reduce inflammation, improve circulation, and relax tense muscles — without compromising your health...

THANK YOU TO TODAY'S SPONSORSMara Labs: Check out https://mara-labs.com/danihealth to get 18% off your order today!Vivarays: Visit vivarays.com & use the code DANIHEALTH for 15% offUBLOCKOUT: Check out ublockout.com & use the code DANI10 for 10% off  Make sure to check out this link to Fullscript.com to get your lifetime 10% discount!TODAY'S GUESTDavid Roberts is the co-founder of Mara Labs, a company known for creating BrocElite, the only supplement with stabilized sulforaphane. He holds a Master of Public Health from Johns Hopkins University and a Master's in Biomedical Engineering from the University of Virginia. With more than 20 years of experience in public health across three continents, David has been instrumental in pioneering natural supplements aimed at supporting gut health and overall wellness. Before co-founding Mara Labs, he also co-founded the gut supplement RESTORE.David's work primarily focuses on the health benefits of natural compounds, particularly sulforaphane, which has been shown to have anti-inflammatory and detoxification properties. He has contributed significantly to the research and development of supplements aimed at enhancing brain health, reducing inflammation, and supporting detox pathways in the body.In addition to his scientific contributions, David enjoys a variety of personal activities, including open-water swimming—he once swam from Alcatraz—and spending time with his two boys in Charlottesville, Virginia. He's also an avid Duke basketball fan and enjoys reading scientific papers in his downtime.Website: Mara-labs.comInstagram:  @themaralabsON TODAY'S EPISODEWhat is sulforaphane, and how is it derived from broccoli?What are the key health benefits of sulforaphane, and how does it support detoxification?In what ways does sulforaphane contribute to brain health and neuroprotection?How does berberine help manage blood glucose levels, and what makes it effective for metabolic health?What surprising benefits does berberine offer for sleep quality and mood?Why are quality and bioavailability so important when it comes to supplements like sulforaphane and berberine?How does the liver play a crucial role in metabolic health and the detoxification process supported by sulforaphane?What are the unique aspects of Moira Labs' sulforaphane supplement, and what guarantees do they offer to customers?How can incorporating sulforaphane and berberine into a health regimen positively impact overall wellness?What practical tips can you share for individuals looking to enhance their health with supplements effectively?STAY IN TOUCH WITH ME:You can find me:On Instagram @daniellehamiltonhealth On Facebook at Danielle Hamilton HealthMy website is daniellehamiltonhealth.comOn my

Do you believe that the more you sell, the quicker demand decreases? The truth is, demand never runs out: demand actually compounds. The idea that demand decreases after selling is a thought error that directly dismisses the fundamental truth of demand and keeps you playing small. Demand exists always and it compounds, grows, and gathers momentum.   Tune in this week to discover the compounding effect of demand. I share why the more you scoop up, the more demand you create over time. Learn about the three types of leads, and why, when some people buy from you, there are always two additional buyer types already warmed up by the selling you've already done.   If you want to start making serious money as a coach, you need to check out 2K for 2K. Click here to join: https://staceyboehman.com/2kfor2k!  

I'm happy to welcome back a previous guest on the podcast. Lynn Wilhite is a licensed clinical social worker who joined me for Episode 263, Coping with Treatment-Resistant Depression. Things have changed for Lynn since she has recently been diagnosed with autism, ADHD, and PTSD. She shares the impact of her diagnoses and how she's making connections about why things were so difficult for her in the past. Her insights help us understand how the many layers and factors of ADHD and autism have complicated her journey. Lynn has paused her work in therapy and social work to focus on her healing, understand her diagnoses, and learn more about her son's autism diagnosis. She feels passionate about bringing neurodivergence into the postpartum conversation, along with normalizing and destigmatizing autism and other forms of neurodivergence for new moms. She is currently writing a book about her postpartum and parenthood journey. Join us to learn more from Lynn's story! Show Highlights: Developments in Lynn's life since her last visit to Mom & Mind The prevalence of parents being diagnosed with autism alongside their children Lynn's diagnostic process—and how her struggles in life began to make sense Stereotypical autism vs. female autism A constant battle of “defending” a diagnosis Medical gaslighting that women have to endure for themselves and their children Autism's part in the challenges of pregnancy and postpartum, even in the smallest details Autism's effects in Lynn's life “Should I have even had a child?” Depression and anxiety are highly comorbid with autism. Masking skills are at their finest in autistic adults. Lynn's biggest lessons learned on her journey The value of support and community Resources: Connect with Lynn Wilhite: Instagram Lynn Wilhite's other Mom & Mind episode:  Episode 263 Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or visit cdph.ca.gov Please find resources in English and Spanish at Postpartum Support International, or by phone/text at 1-800-944-4773. There are many free resources, like online support groups, peer mentors, a specialist provider directory, and perinatal mental health training for therapists, physicians, nurses, doulas, and anyone who wants to be more supportive in offering services.  You can also follow PSI on social media: Instagram, Facebook, and most other platforms Visit www.postpartum.net/professionals/certificate-trainings/ for information on the grief course.   Visit my website, www.wellmindperinatal.com, for more information, resources, and courses you can take today! If you are a California resident looking for a therapist in perinatal mental health, email me about openings for private pay clients!